References
Auffret M, Labreuche J, Duhamel A et al. Proactive regional pharmacovigilance system versus National Spontaneous Reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France. Drug Saf. 2016;40(3). doi:10.1007/s40264-016-0489-7.
Braillon A, Lexchin J. Off-label drug use: whose interests are served? Am J Med Qual. 2016;31:285.
Agence Française de Sécurité Sanitaire des Produits de Santé. Warning against off-label use of baclofen in the treatment of alcohol use disorders. 2001. http://ansm.sante.fr/var/ansm_site/storage/original/application/b88517d4324d10054712c930f22c464b.pdf.
Degrassat-Théas A, Bocquet F, Sinègre M, Peigné J, Paubel P. The, “Temporary Recommendations for Use”: a dual-purpose regulatory framework for off-label drug use in France. Health Policy. 2015;119:1399–405.
Olivier PY, Joyeux-Faure M, Gentina T, et al. Severe central sleep apnea associated with chronic baclofen therapy: a case series. Chest. 2016;149:e127–31.
Baumann S, Toft U, Aadahl M, et al. The long-term effect of a population-based life-style intervention on smoking and alcohol consumption. The Inter99 study—a randomized controlled trial. Addiction. 2015;110:1853–60.
Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016;26:1950–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to assist in the preparation of this letter.
Conflict of interest
Alain Braillon was a co-investigator for the trial NCT01738282 (baclofen), but did not include patients. He is an expert for several task force groups (related to neither addiction nor psychiatry) at Agence Française de Sécurité Sanitaire des Produits de Santé.
Rights and permissions
About this article
Cite this article
Braillon, A. Comment on: “Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France”. Drug Saf 40, 359–360 (2017). https://doi.org/10.1007/s40264-017-0512-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-017-0512-7